Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax Inc (NASDAQ:NVAX) announced a wide-ranging partnership with Sanofi, which includes lead commercial responsibilities for the COVID-19 vaccine starting with the 2025-2026 vaccination season.

John Trizzino, our President and Chief Operating Officer who will provide an update on our Sanofi partnership and finally Jim Kelly, Chief Financial Officer and Treasurer who will provide an ...

Novavax NVAX incurred a fourth-quarter 2024 loss of ... loss of $1.23 per share compared with a loss of $5.41 in 2023. With Sanofi now responsible for marketing the company’s COVID-19 vaccine ...

Since Novavax is reliant on Sanofi’s sales forecasts for certain ... while the street low from HC Wainwright & Co. is $19.0. Price Action: NVAX stock is up 10.4% at $8.08 at the last check ...

Several large investors have recently modified their holdings of NVAX. Sanofi purchased a new position in shares of Novavax in the fourth quarter worth about $55,319,000. Deep Track Capital LP ...

Despite potential opportunities, NVAX stock remains a “Sell” due ... royalties and other — primarily due to the deal with Sanofi. Total expenses were $931m, down from >$1.5bn in the prior ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price ... mix of high-efficacy and improved safety that, with Sanofi’s (SNY) marketing muscle, could become a “significant ...

B. Riley cut their Q1 2025 earnings per share estimates for Novavax in a report issued on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post ...

NVAX reports encouraging fourth-quarter results ... Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines ...